Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000204025 | SCV000259769 | uncertain significance | Hereditary nonpolyposis colon cancer | 2018-10-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with glutamic acid at codon 373 of the MLH1 protein (p.Gly373Glu). The glycine residue is weakly conserved and there is a moderate physicochemical difference between glycine and glutamic acid. This variant is present in population databases (rs774878513, ExAC 0.002%). This variant has not been reported in the literature in individuals with MLH1-related disease. ClinVar contains an entry for this variant (Variation ID: 219728). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV000221361 | SCV000275661 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-09-27 | criteria provided, single submitter | clinical testing | Lines of evidence used in support of classification: Insufficient or conflicting evidence |
| Fulgent Genetics, |
RCV000764488 | SCV000895559 | uncertain significance | Turcot syndrome; Muir-Torré syndrome; Lynch syndrome II | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Color | RCV000221361 | SCV000906867 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-07-12 | criteria provided, single submitter | clinical testing |